Small Cell Lung Carcinoma Archives | MSD Oncology Clinical Trials

Condition: Small Cell Lung Carcinoma

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.

Pembrolizumab/Vibostolimab or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer

May 20, 2022

By Tyler Kalist

Safety and Efficacy Study of Pembrolizumab in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy

March 10, 2022

By Support_Clique

This study is a rolling arm study of pembrolizumab in combination with investigational agents in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in

Study of Pembrolizumab in Participants With Advanced Solid Tumors

March 7, 2022

By Support_Clique

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).